Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MESO 
Mesoblast Ltd (MESO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: MESO (3-star) is a STRONG-BUY. BUY since 29 days. Profits (8.87%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $27
1 Year Target Price $27
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 584.5% | Avg. Invested days 39 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.07B USD | Price to earnings Ratio - | 1Y Target Price 27 |
Price to earnings Ratio - | 1Y Target Price 27 | ||
Volume (30-day avg) 3 | Beta 1.32 | 52 Weeks Range 6.00 - 22.00 | Updated Date 08/29/2025 |
52 Weeks Range 6.00 - 22.00 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.31 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date 2025-08-28 | When - | Estimate -0.4 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -633.21% |
Management Effectiveness
Return on Assets (TTM) -4.85% | Return on Equity (TTM) -21.31% |
Valuation
Trailing PE - | Forward PE 454.55 | Enterprise Value 2099503836 | Price to Sales(TTM) 364.94 |
Enterprise Value 2099503836 | Price to Sales(TTM) 364.94 | ||
Enterprise Value to Revenue 137.12 | Enterprise Value to EBITDA -6.55 | Shares Outstanding 127942000 | Shares Floating 708430639 |
Shares Outstanding 127942000 | Shares Floating 708430639 | ||
Percent Insiders 0.06 | Percent Institutions 2.69 |
Upturn AI SWOT
Mesoblast Ltd
Company Overview
History and Background
Mesoblast Ltd was founded in 2004 in Australia and is a global regenerative medicine company. It focuses on developing and commercializing innovative cellular medicines to treat inflammatory diseases. Key milestones include clinical trial successes and regulatory approvals for its products.
Core Business Areas
- Cellular Medicines: Developing and commercializing proprietary allogeneic (off-the-shelf) cellular medicines.
- Remestemcel-L: Developing and commercializing Remestemcel-L, a cell therapy product targeting inflammatory conditions.
Leadership and Structure
The company has a board of directors and an executive management team. Key positions include the CEO, CFO, and Chief Medical Officer.
Top Products and Market Share
Key Offerings
- Remestemcel-L: Remestemcel-L is Mesoblast's lead product candidate, an allogeneic mesenchymal stromal cell (MSC) therapy initially targeting steroid-refractory acute graft versus host disease (SR-aGVHD) in children. The competitors for this product are companies developing other treatments for aGVHD, including Incyte (Jakafi), and emerging cell therapies. Market share data is unavailable, but Mesoblast is a major player in the cell therapy space for aGVHD.
Market Dynamics
Industry Overview
The regenerative medicine industry is growing, driven by increasing demand for new treatments for chronic diseases. Cell therapies are at the forefront of this growth.
Positioning
Mesoblast is positioned as a leading company in the regenerative medicine space, with a focus on cell therapies for inflammatory diseases. Its competitive advantage lies in its proprietary MSC technology and advanced clinical programs.
Total Addressable Market (TAM)
The total addressable market for cell therapies is estimated to be worth billions of dollars. Mesoblast is positioned to capture a significant portion of this market with its Remestemcel-L product candidate.
Upturn SWOT Analysis
Strengths
- Proprietary MSC technology platform
- Advanced clinical programs
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- High R&D costs
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Limited commercialization experience
Opportunities
- Expanding clinical applications for Remestemcel-L
- Partnering with pharmaceutical companies
- Acquiring complementary technologies
- Entering new markets
Threats
- Clinical trial failures
- Regulatory rejections
- Competition from new therapies
- Economic downturns
Competitors and Market Share
Key Competitors
- INCY
- BMY
- CRSP
Competitive Landscape
Mesoblast faces competition from established pharmaceutical companies and other regenerative medicine companies. Its competitive advantage lies in its proprietary MSC technology and advanced clinical programs, but it needs to successfully commercialize its products to maintain its position.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is unavailable to provide.
Future Projections: Analyst estimates suggest continued growth in revenue driven by potential approvals and commercialization of Remestemcel-L.
Recent Initiatives: Recent initiatives include advancing clinical trials, seeking regulatory approvals, and expanding manufacturing capacity.
Summary
Mesoblast is a promising regenerative medicine company with a focus on cell therapies. Its lead product candidate, Remestemcel-L, has shown potential in treating inflammatory conditions. However, the company faces challenges related to regulatory hurdles and commercialization. Successful approval and market penetration of Remestemcel-L are crucial for its future success. The company must also navigate a competitive landscape and manage its high R&D costs.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry News
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise. Financial data should be validated with official company filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mesoblast Ltd
Exchange NASDAQ | Headquaters Melbourne, VIC, Australia | ||
IPO Launch date 2015-11-13 | Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) | ||
Sector Healthcare | Industry Biotechnology | Full time employees 73 | Website https://www.mesoblast.com |
Full time employees 73 | Website https://www.mesoblast.com | ||
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.